Summary Serial CA125 measurements in 169 patients with epithelial ovarian carcinoma were obtained. Changes in serum CA125 measurements are shown to reflect changes in clinical status. For patients with macroscopic disease receiving chemotherapy, the sensitivity and specificity for predicting response are shown to be 95% and 86% respectively. For patients with no known disease, the sensitivity and specificity for detecting relapse are shown to be 86% and 91 % respectively. The clinical correlates with the level of serum CA125 were examined and the most important is shown to be amount of residual disease.
CA125 is the antigen recognised by the monoclonal antibody, OC125, produced by immunising BALB/c mice with a cell line OVCA 433 cultured from the ascitic fluid of a patient with a papillary serous cystadenocarcinoma of the ovary and using somatic hybridisation of the spleen cells with a mouse myeloma (Bast et al., 1981) . Initially it was thought to be specific for ovarian malignancy (Bast et al., 1981; Kabawat et al., 1983a) of the serous, endometrioid and clear cell types but it was subsequently shown to be a high-molecular-weight glycoprotein expressed on coelomic epithelium during embryonic development (Kabawat et al., 1983b) .
As multiple antigenic determinants are present on each molecule of the protein an immunoradiometric assay for free serum CA125 was developed (Klug et al., 1984) . Using this, normal values have been determined and it has also been established that CA125 values are raised in the serum of patients with a variety of other malignancies (Klug et al., 1984) ; in particular mucinous carcinoma of the ovary (Canney et al., 1984) and gastrointestinal malignancies (Haga et al., 1986a) . CA125 is also found to be raised in a variety of benign conditions including pregnancy, pelvic inflammatory disease (Haga et al., 1986b; Halila et al., 1986) and cirrhosis (Bergmann et al., 1987) . In view of this the exact origin of the antigen is uncertain and it has recently been suggested that CA125 may be a marker of ascites (Bergmann et al., 1987) or non-specific peritoneal damage (Redman et al., 1988) .
Unfortunately it would appear that CA125 is neither specific enough nor sensitive enough to be used alone as a screening test for early carcinoma of the ovary (Heinonen et al., 1985) . It has been shown, however, that CA125 is useful in the monitoring of patients undergoing treatment for carcinoma of the ovary (Bast et al., 1983; Canney et al., 1984; Heinonen et al., 1985) as the change in level of antigen is correlated well with response status.
We set out here to determine how effective CA125 is in a routine clinical setting for: (a) (1989), 60, 634-637 '." The Macmillan Press Ltd., 1989 was taken as the minimum from which response could be accurately measured). Correlation of CA125 measurements with various factors was examined initially using univariate methods and x2 tests. To try to identify the most important correlates further factor analysis was carried out using multiple linear regression performed with the standard MINITAB program. In the linear regression model the following coding was used -CA125 (<35 Um[l-=0, 35-65Uml-'=1, 65-130 Uml-'=2, 130-250Uml-'=3, 250-50 OUml-'=4, >500 Uml-'=5), residual (<2cm=0, 2-5 cm=l, >5cm=2), stage (III = 0, IV = 1), ascites (nil = 0, small = 1, moderate/ large = 2), histology (as stated in results section).
Results
Monitoring ofpatients with macroscopic disease during treatment There were 89 patients who had adequate assessment of response by clinical methods and had CA 125 measurements at appropriate times to detect response. They had been treated mainly with platinum compounds (Table II) ever, stable disease is a useful end-point; when all three categories (response, no change, progressive disease) are considered overall agreement occurs in 63 out of 88 (72%) events assessable by both methods.
Monitoring ofpatients with no known disease There were 73 patients with satisfactory assessment by both clinical methods and CA125 measurement: of these 23 were monitored after initial surgery, 16 of which were stage I, while 50 were in clinical and radiological CR after previous treatment. Again the overall agreement was excellent, as shown in Table IV . Of the two patients who relapsed clinically but not using CA125, one was found at a follow-up laparoscopy to be cytology positive only but one was found on clinical examination to have a small recurrence at the vault of the vagina; this was confirmed at laparatomy and was the only disease identified. Of the five who relapsed using CA125 but not clinically one had a transient rise in CA125 (only on one occasion was the CA125 level >65 U ml' but it rose gradually over 4 months and then fell again spontaneously, eventually both CA125 and clinical status suggesting that the patient remained in CR. A further three who had relapsed using CA125 but not clinically by the end of the study subsequently relapsed (up to 6 months later); only one still has an elevated CA125 (level>300 Uml-1') 12 months later and yet remains clinically well with no sign of recurrence.
In general CA125 measurement gave a moderate lead time in predicting relapse so that in the 12 who had relapsed on both methods the mean lead time was approximately 2 months for CA125 (median one month).
Factors associated with a raised CA 125 Univariate analysis suggested that amount of residual disease, stage, amount of ascites and histology were correlated with CA 125 (data not shown). For histology the coding which gave the best correlation was 1 = mucinous, 2 = undifferentiated adenocarcinoma, 3 = endometrioid, 4 = serous (clear cell omitted as there were so few). In order to try to elucidate this further, since these factors are likely to be interrelated, we carried out a multivariate analysis using a standard forward selection method.
The results in Table V are given for newly diagnosed patients with macroscopic disease at initial surgery (46 patients) and then for all patients, including those who have 
Discussion
We confirm previous studies (Bast et al., 1983; Canney et al., 1984; Heinonen et al., 1985) Hook effects seem likely to only be a very occasional problem as in the CA 125 assay a serum level of over 20,000 U ml' (data on file CIS(UK)) must be reached before the apparent level falls below 500 U ml-' and this is rare (none out of 101 patients in Bast et al. (1983) ). It is possible that the overall usefulness could be improved if dilutions were carried out so that levels above 500 U ml' could be measured. We have no data on the other possibilities.
Following patients in CR or stage I patients compared favourably with our current methods of follow-up using CT and ultrasound scans and more rarely laparoscopy or laparotomy; this was also shown by Niloff et al. (1986 The origin of the measured CA125 is uncertain (Bergmann et al., 1987) . In addition to direct production by tumour cells another possible site of antigen production is reactive mesothelial cells in the peritoneum (or pleura) since using sensitive techniques (Kabawat et al., 1983b) these are shown to express surface CA125. This site of origin is suggested by Bergmann et al. (1987) because of their evidence of raised levels in cirrhosis, especially with ascites, and because it was shown by Heinonen et al. (1985) that the level of antigen in the ovarian vein of patients with ovarian carcinoma is little different to that in a peripheral vein. This site of production is also favoured by the fact that non-specific insults to the peritoneum such as laparotomy may elevate the serum CA125 (Redman et al., 1988 ). Fleuren et al. (1987 suggest an alternative hypothesis that the peritoneum acts as a barrier between the CA125 produced by the tumour and the circulation and it is only when that is breached by malignant infiltration that the serum CA125 becomes elevated. Perhaps a combination of all these possibilities may occur. We have no direct data on the possible origin of CA125 and either origin would be consistent with our data as the amount of disease also tends to reflect the amount of involved peritoneum (and pleura). Further experimental evidence would be necessary to elucidate this.
This study confirms that CA125 is a sensitive and specific means of monitoring patients with ovarian carcinoma. Combined with other studies it suggests that in those patients who have an elevated level after surgery CA125 could be used as the major means of monitoring therapy until the CA 125 reaches normal levels. At that stage it cannot be assumed that there is no disease present and other methods of monitoring must be used. If the CA125 fails to reach normal levels, or rises after falling, a switch to alternative treatment is indicated if a useful alternative is available. Similarly those who achieve CR or who have stage I disease could be followed primarily with CA 125 measurement. Treatment should be considered if CA 125 begins to rise without other explanation (e.g. cirrhosis, peritoneal inflammation).
Strategies such as those suggested above are strikingly similar to those used so effectively in the treatment of teratomas using alpha-fetoprotein as a tumour marker. If further study of serial CA 125 levels confirm these results then fewer unpleasant and expensive scans may need to be done.
